Glaxosmithkline Biologicals Sa

Utrecht University

Christiane Feron

Jan Poolman

Ralph Leon Biemans

Philippe Denoel

Joelle Thonnard

Vincent Weynants

Yves Lobet

Carine Goraj

Guy Dequesne

Georges Thiry

Francois-Xavier Jacques Berthet

Jan Tommassen

Nathalie Devos

Wilfred L J Dalemans

The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtBis shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS invaccine compositions. Bleb vaccines derived from lgtBand capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis

The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtBis shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS invaccine compositions. Bleb vaccines derived from lgtBand capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

[object Object]

Growing community of inventors

Rixensart, Belgium

Christiane Feron